Shenzhen Cell Inspire Biotechnology

Cell-Inspire Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, dedicated to the discovery and development of next-generation immune cell therapies. The company focuses on addressing the challenges of treating solid tumors using its proprietary CAR-T, TCR-T, and TIL technology platforms. Its lead candidate, CI-T001, is a GPC3-targeted CAR-T therapy currently being evaluated for the treatment of advanced hepatocellular carcinoma. Another key program, CI-T002, targets Claudin 18.2 for gastric and pancreatic cancers. By optimizing cell persistence and infiltration within the tumor microenvironment, Cell-Inspire aims to deliver breakthrough treatments for patients with limited therapeutic options. The company operates a state-of-the-art GMP manufacturing facility to support its clinical pipeline and future commercialization efforts.